Study of Some Hyndantion Derivatives as Anticonvulsant Agents

Abida, .; Tauquir Alam, Md; Asif, Mohammad

doi:10.33945/SAMI/PCBR.2020.2.2

Document Type : Original Research Article

Authors

¹ Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Northern Border University, Rafha 91911, PO Box 840, Saudi Arabia

² Department of Pharmacy, Himalayan Institute of Pharmacy and Research, Dehradun, (Uttarakhand), 248007, India

https://doi.org/10.33945/SAMI/PCBR.2020.2.2

Abstract

Hydantoin derivatives are commonly used anticonvulsant drugs. It is generally effective against partial and tonic-clonic seizures but not in absent seizures. Phenytoin is the main drug of this group and other drugs ethotoin, mephenytoin also commonly used in the therapy of epilepsies. However, they have some adverse effects and long period of therapy to seizure control. To sort out these problems, various new hydantoin derivatives as well as prodrugs like fosphenytoin were prepared. Phenytoin is effective in some cases of trigeminal and related neuralgias. Phenytoin is also used in the treatment of cardiac arrhythmias.

Graphical Abstract

Keywords

20.1001.1.26767090.2020.3.2.2.8

Main Subjects

Full Text

References

REFERENCRES

[1]. B. Malawska, Curr Topics Med Chem, 5(2005), 69.

[2]. E. Shek, Adv. Drug Delivery Rev, 14(1994), 227.

[3]. J. Bosch, Bioorg. Med. Chem. Lett., 9(1999), 1859.

[4]. C. Yang, and A. Mitra, J. Pharm. Sci., 90 (2001), 340.

[5]. R.V. Wagh, R.V. Antre, R.J. Oswal, and H.M. Nimje, J Pharm Res & Bio-Sci Res, 1(3): 2011, 142-147.

[6]. A.C. Gerlach, and J.L. Krajewski Pharmaceuticals, 3(2010), 2884-2899.

[7]. M. Bialer, Epilepsy Res, 15(2006):637-647.

[8]. D. Chisholm, Epilepsia, 46 (2005), 751-759.

[9]. M.A. Rogawski, and W. Loscher, Nat. Rev. Neurosci., 5(2004), 553-564.

[10]. P. Kwan, and J.W. Sander, J. Neurol. Neurosurg. Psychiatry, 75(2004), 1376-1381.

[11]. C. Dwivedi Am. J. Pharm. Educ., 65(2001), 197-202.

[12]. R.L. Macdonald, and L.J. Jr. Greenfield, Curr. Opin. Neurol., 10 (1997), 121-128.

[13]. M.J. McLean, and R.L. Macdonald, J. Pharmacol. Exp. Ther., 238(1986), 727-738.

[14]. S. Botros, N.A. Khalil, B.H. Naguib, Y. El-Dash, Eur J Med Chem., 60 (2013), 57-63.

[15]. C.O. Usifoh, Arch Pharm (Weinheim), 334(2001):366-8.

[16]. M. Deodhar, P. Sable, A. Bhosale, K. Juvale, R. Dumbare, P. Sakpal, Turk J Chem, 33(2009), 1-7.

[17]. D.M. Lambert, B. Masereel, B. Gallez, M, Geurts, and G.K. Scriba, J Pharm Sci.,85(1996), 1077-81.

[18]. G.K. Scriba, D.M. Lambert, and J.H. Poupaert, J Pharm Pharmacol, 47(1995), 197-203.

[19]. J, Karolak-Wojciechowska, W. Kwiatkowski, and K. Kiec-Kononowicz, Pharmazie, 50(1995), 114-7.

[20]. T. Ogiso, T. Tanino, M. Iwaki, O. Muraoka, and G. Tanabe, Biol Pharm Bull., 17(1994), 1425-9.

[21]. G.K. Scriba, Pharm Res., 10(1993):1181-6.

[22]. C.H. Kwon, M.T. Iqbal, and J.N. Wurpel. J Med Chem., 34(1991), 1845-9.

[23]. W. Fürst, and R. Wildner. Pharmazie, 46(1991), 424-6.

[24]. M.A. Moustafa, A.A. el-Emam, H.I. Subbagh, and M.K. el-Din, Arzneimittelforschung, 40(1990), 1076-8.

[25]. J. Lange, and J. Lapszewicz, Acta Pol Pharm., 47(1990), 31-4.

[26]. P.T. Wong,, S.T. Tan, and H.S. Lee. Jpn J Pharmacol., 48(1988), 473-8.

[27]. A.J. Glazko, Ther Drug Monit.,;9(1987), 407-15.

[28]. H. Fujioka, T. Tan, M. Kishi, H. Miyazaki, Y. Masuda, and Y. Yokoyama. J Pharmacobiodyn, 9(1986), 303-14.

[29]. K. Kieć-Kononowicz, E. Stypuła, J. Krupińska, and B. Cebo, Pol J Pharmacol Pharm. 1985, 37(1985)693-9.

[30]. R. Jalilian, M. Shahmari, A. Taheri, K. Gholami, Ultrason Sonochem, 61(2020) 104802.

[31]. R. Jalilian, A. Taheri, e-Polymers, 18(2018) 123..

[32]. W.L. Nelson, Y.G. Kwon, G.L. Marshall, J.L. Hoover, and G.T. Pfeffer. J Pharm Sci, 68(1979), 115-7.

[33]. A. Zejc, M. and Pawlłowski, Pol J Pharmacol Pharm, 32(1980),173-8.

[34]. J. Bosch, T. Roca, J. Domènech, and M. Suriol. Bioorg Med Chem Lett,. 5(1999), 1859-62.

[35]. T.R. Browne. Clin Neuropharmacol., 20(1997), 1-12.

[36]. B.A. Boucher, Pharmacother, 16(1996), 777-91.

[37]. E.K. Hussey, G.E. Dukes, J.A. Messenheimer, K.L. Brouwer, K.H. Donn, T.F. Krol, and L.J. Hak, Pharm Res, 7(1990), 1172-6.

[38]. B.D. Jamerson, K.H. Donn, G.E. Dukes, J.A. Messenheimer, K.L. Brouwer, and J.R. Powell, Epilepsia, 31(1990),592-7.

[39]. N.Y. Walton, and D.M. Treiman, Epilepsy Res, 5(1990), 165-8.

[40]. B.A. Boucher, A.M. Bombassaro, S.N. Rasmussen, C.B. Watridge, R. Achari, and P. Turlapaty, J Pharm Sci., 78(1989),929-32.

[41]. S.S.H. Davarani, Z. Rezayati-zad, A. Taheri, N. Rahmatian, Materials science & engineering C, Materials for biological applications, 71(2017) 572-83..

[42]. T.R. Browne, H. Davoudi, K.H. Donn, C.L. Dougherty, G.E. Dukes, B. Evans, J.E. Evans, B. Jamerson, J. Kres, C.M. McEntegart, et al., Epilepsia. 30 Suppl2(1989), S27-32.

[43]. I.E. Leppik, R. Boucher, B.J. Wilder, V.S. Murthy, C.A. Rask, C. Watridge, N.M. Graves, R.J. Rangel, and P. Turlapaty, Epilepsia. 30Suppl2 (1989), S22-6.

[44]. N. Gerber, D.C. Mays, K.H. Donn, A. Laddu, R.M. Guthrie, P. Turlapaty, C.Y. Quon, and W.K. Rivenburg, J ClinPharmacol.,28(1988) 1023-32.

[45]. S. Rump, I. Ilczuk, K. Walczyna, E. Zadrozyńska, Monogr Neural Sci., 5(1980),163-7.

[46]. K. Kieć-Kononowicz, and A. Zejc, Acta Pol Pharm., 38(1981), 49-53.

HOW TO CITE THIS ARTICLE
Abida, Md Tauquir Alam and Mohammad Asif, Study of Some Hyndantion Derivatives as Antivonvulsant Agents, Prog. Chem. Biochem. Res. 2020, 3(2), 93-104.

DOI: 10.33945/SAMI/PCBR.2020.2.2
URL: http://www.pcbiochemres.com/article_106475.html

Progress in Chemical and Biochemical Research

Study of Some Hyndantion Derivatives as Anticonvulsant Agents

Full Text

Full Text

References

References

Volume 3, Issue 2
May 2020
Pages 93-104

Study of Some Hyndantion Derivatives as Anticonvulsant Agents

Full Text

Full Text

References

References

Volume 3, Issue 2May 2020Pages 93-104

Volume 3, Issue 2
May 2020
Pages 93-104